4.7 Article

Rutaecarpine Increases Anticancer Drug Sensitivity in Drug-Resistant Cells through MARCH8-Dependent ABCB1 Degradation

期刊

BIOMEDICINES
卷 9, 期 9, 页码 -

出版社

MDPI
DOI: 10.3390/biomedicines9091143

关键词

rutaecarpine; multidrug resistance (MDR); ABCB1; MARCH8; ubiquitination

资金

  1. Natural Science Foundation Project of CQ CSTC [cstc2020jcyj-msxmX0154]
  2. National Natural Science Foundation of China [31571454, 31871378, 32060148]

向作者/读者索取更多资源

The study reveals that rutaecarpine can reverse ABCB1-mediated multidrug resistance by promoting the degradation of ABCB1 protein through increasing the protein level of MARCH8. This approach of co-administering rutaecarpine with conventional chemotherapeutic agents shows therapeutic effects on transplanted tumors.
The overexpression of adenosine triphosphate (ATP)-binding cassette (ABC) subfamily B member 1 (ABCB1; P-glycoprotein; MDR1) in some types of cancer cells is one of the mechanisms responsible for the development of multidrug resistance (MDR), which leads to the failure of chemotherapy. Therefore, it is important to inhibit the activity or reduce the expression level of ABCB1 to maintain an effective intracellular level of chemotherapeutic drugs. In this study, we found that rutaecarpine, a bioactive alkaloid isolated from Evodia Rutaecarpa, has the capacity to reverse ABCB1-mediated MDR. Our data indicated that the reversal effect of rutaecarpine was related to the attenuation of the protein level of ABCB1. Mechanistically, we demonstrated that ABCB1 is a newly discovered substrate of E3 ubiquitin ligase membrane-associated RING-CH 8 (MARCH8). MARCH8 can interact with ABCB1 and promote its ubiquitination and degradation. In short, rutaecarpine increased the degradation of ABCB1 protein by upregulating the protein level of MARCH8, thereby antagonizing ABCB1-mediated MDR. Notably, the treatment of rutaecarpine combined with other anticancer drugs exhibits a therapeutic effect on transplanted tumors. Therefore, our study provides a potential chemotherapeutic strategy of co-administrating rutaecarpine with other conventional chemotherapeutic agents to overcome MDR and improve therapeutic effect.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据